Neonatal intrahippocampal injection of lipopolysaccharide induces deficits in social behavior and prepulse inhibition and microglial activation in rats: Implication for a new schizophrenia animal model

Brain, Behavior, and Immunity

Volumn 38, Issue , 2014, Pages 166-174

  Zhu, Furong ^a   Zhang, Lulu ^b   Ding, Yu qiang ^a   Zhao, Jingping ^a   Zheng, Yingjun ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Animal model; Lipopolysaccharide; Microglia; Schizophrenia

Indexed keywords

LIPOPOLYSACCHARIDE; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BRAIN CORTEX; CELL ACTIVATION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MACROPHAGE; MICROGLIA; NEUROPATHOLOGY; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION; THALAMUS; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; INJECTION; MALE; METABOLISM; MOTOR ACTIVITY; NEWBORN; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; ADULT; ANIMAL TISSUE; BEHAVIOR DISORDER; DRUG EFFECT; EMBRYO; LOCOMOTION;

ANIMALS; ANIMALS, NEWBORN; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; INJECTIONS; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; MOTOR ACTIVITY; PREPULSE INHIBITION; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

EID: 84898545352     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.01.017     Document Type: Article

References (32)

1. Amann L.C., Gandal M.J., Halene T.B., Ehrlichman R.S., White S.L., McCarren H.S., Siegel S.J. Mouse behavioral endophenotypes for schizophrenia. Brain Res. Bull. 2010, 83:147-161.
2. Bayer T.A., Buslei R., Havas L., Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 1999, 271:126-128.
3. Bessis A., Bechade C., Bernard D., Roumier A. Microglial control of neuronal death and synaptic properties. Glia 2007, 55:233-238.
4. Chaudhry I.B., Hallak J., Husain N., Minhas F., Stirling J., Richardson P., Dursun S., et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012, 26:1185-1193.
5. Chen X.S., Zhang C., Xu Y.F., Zhang M.D., Lou F.Y., Chen C., Tang J. Neonatal ventral hippocampal lesion as a valid model of schizophrenia: evidence from sensory gating study. Chin. Med. J. (Engl.) 2012, 125:2752-2754.
6. Doorduin J., de Vries E.F., Willemsen A.T., Dierckx R.A., Klein H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med. 2009, 50:1801-1807.
7. Fagan S.C., Edwards D.J., Borlongan C.V.Xu., Arora L., Feuerstein A., Hess G. Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp. Neurol. 2004, 186:248-251.
8. Fan L.W., Pang Y., Lin S., Tien L.T., Ma T., Rhodes P.G., Cai Z. Minocycline reduces lipopolysaccharide-induced neurological dysfunction and brain injury in the neonatal rat. J. Neurosci. Res. 2005, 82:71-82.
9. Feleder C., Tseng K.Y., Calhoon G.G., O'Donnell P. Neonatal intrahippocampal immune challenge alters dopamine modulation of prefrontal cortical interneurons in adult rats. Biol. Psychiatry. 2010, 67:386-392.
10. Galic M.A., Riazi K., Henderson A.K., Tsutsui S., Pittman Q.J. Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol. Dis. 2009, 36:343-351.
11. Graeber M.B., Streit W.J. Microglia: biology and pathology. Acta Neuropathol. 2010, 119:89-105.
12. Heckers S., Konradi C. Hippocampal pathology in schizophrenia. Curr. Top. Behav. Neurosci. 2010, 4:529-553.
13. Jhamnani K., Shivakumar V., Kalmady S., Rao N.P., Venkatasubramanian G. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 2013, 25:E06-E07.
14. Kubo K.I., Nakajima K. Neuronal distribution in the cerebral cortex and its significance in schizophrenia. Brain Nerve 2013, 65:1133-1145.
15. Lee S.Y., Kim B., Jeong H.K., Min K.J., Liu T., Park J.Y., Joe E.H., et al. Enhanced phosphatidylinositol 4-phosphate 5-kinase alpha expression and PI(4,5)P2 production in LPS-stimulated microglia. Neurochem. Int. 2010, 57:600-607.
16. Levkovitz Y., Levi U., Braw Y., Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007, 1154:154-162.
17. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., Fennig S., et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 2010, 71:138-149.
18. Meyer U., Feldon J., Schedlowski M., Yee B.K. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci. Biobehav. Rev. 2005, 29:913-947.
19. Meyer U., Nyffeler M., Yee B.K., Knuesel I., Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav. Immun. 2008, 22:469-486.
20. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., Yamauchi Y., et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:115-121.
21. Pinault D. Dysfunctional thalamus-related networks in schizophrenia. Schizophr. Bull. 2011, 37:238-243.
22. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63:801-808.
23. Powell C.M., Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol. Psychiatry 2006, 59:1198-1207.
24. Ratnayake U., Quinn T.A., Castillo-Melendez M., Dickinson H., Walker D.W. Behaviour and hippocampus-specific changes in spiny mouse neonates after treatment of the mother with the viral-mimetic Poly I: C at mid-pregnancy. Brain Behav. Immun. 2012, 26:1288-1299.
25. Sams-Dodd F., Lipska B.K., Weinberger D.R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacol. (Berl.) 1997, 132:303-310.
26. Schneider T., Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
27. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 2000, 24:417-463.
28. Takano A., Arakawa R., Ito H., Tateno A., Takahashi H., Matsumoto R., Okubo Y., et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int. J. Neuropsychopharmacol. 2010, 13:943-950.
29. Van Van Amersfoort E.S., Berkel T.J., Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin. Microbiol. Rev. 2003, 16:379-414.
30. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 2008, 64:820-822.
31. Zhang L., Kitaichi K., Fujimoto Y., Nakayama H., Shimizu E., Iyo M., Hashimoto K. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1381-1393.
32. Zhang L., Shirayama Y., Iyo M., Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007, 32:2004-2010.